초록 ▼

Aspects of the invention provides methods for preparing and using adipose-tissue-derived stem and progenitor cells, adipose-tissue-derived lymphatic endothelial cells, and cells capable of differentiating into lymphatic endothelial cells to treat disorders of the lymphatic system and to modulate exp

Aspects of the invention provides methods for preparing and using adipose-tissue-derived stem and progenitor cells, adipose-tissue-derived lymphatic endothelial cells, and cells capable of differentiating into lymphatic endothelial cells to treat disorders of the lymphatic system and to modulate expansion, repair, and/or regeneration of the lymphatic system. The invention further provides using adipose-tissue-derived lymphatic endothelial cells and cells capable of differentiating into lymphatic endothelial cells for delivery of therapeutic agents to tumor cells as a means for treating malignant disease, and assays to screen for drugs that modulate lymphatic system expansion, repair or regeneration.

대표청구항 ▼

1. A method of lymphatic endothelial cell (LEC) and pre-LEC transplantation in a mammal comprising: identifying a mammal in need of LECs or pre-LECs; andproviding an isolated population of adipose-derived cells comprising lymphatic endothelial cells (LECs) and pre-LECs, wherein greater than 5% of sa

1. A method of lymphatic endothelial cell (LEC) and pre-LEC transplantation in a mammal comprising: identifying a mammal in need of LECs or pre-LECs; andproviding an isolated population of adipose-derived cells comprising lymphatic endothelial cells (LECs) and pre-LECs, wherein greater than 5% of said population of adipose-derived cells express FLT-4, to said identified mammal. 2. The method of claim 1, wherein said isolated population of adipose-derived cells is mixed with a biological material, an additive, a medical device, a prosthetic, a cell differentiation factor, a growth promoter, an immunosuppressive agent, an anti-apoptosis agent, a biological tissue, a tissue graft, a portion of unprocessed adipose tissue, a collagen, a population of adipose-derived stem cells, a population of adipose-derived endothelial cells, or a population of adipose derived progenitor cells. 3. The method of claim 1, further comprising assessing said mammal for induction of lymphatic cell proliferation, lymphatic cell expansion, lymphatic vessel formation, or lymphatic tissue formation. 4. The method of claim 1, wherein said cell transplantation accompanies a breast augmentation procedure. 5. A method of inducing expansion of lymph vessels in a mammal comprising: identifying a mammal in need of an expansion of lymph vessels; andproviding an isolated population of adipose-derived cells comprising lymphatic endothelial cells (LECs) and pre-LECs, wherein greater than 5% of said population of adipose-derived cells express FLT-4, to said identified mammal. 6. The method of claim 5, wherein said isolated population of adipose-derived cells is mixed with a biological material, an additive, a medical device, a prosthetic, a cell differentiation factor, a growth promoter, an immunosuppressive agent, an anti-apoptosis agent, a biological tissue, a tissue graft, a portion of unprocessed adipose tissue, a collagen, a population of adipose-derived stem cells, a population of adipose-derived endothelial cells, or a population of adipose derived progenitor cells. 7. The method of claim 5, further comprising assessing said mammal for one or more of the following: induction of lymphatic cell proliferation, lymphatic cell expansion, lymphatic vessel formation, and lymphatic tissue formation. 8. The method of claim 5, wherein said providing step accompanies a breast augmentation procedure.